Return to the catalog
FOXO4-DRI
NewOut of stock10mg vial

FOXO4-DRI

Designer peptide studied for clearing out old, worn-out "senescent" cells linked to ageing.

For Research Use Only

Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.

Pricing coming soon

Contact us for a quote on this batch.

Bacteriostatic water included

99%+ Purity
Extensively Researched

About this peptide

FOXO4-DRI is an engineered research peptide built with reversed 'mirror-image' (D-form) amino acids—a molecular modification designed to resist rapid breakdown by the body's natural enzymes, allowing it to remain stable and active far longer. As cells age, some stop dividing but refuse to die — these "senescent" cells build up and release inflammatory signals. FOXO4-DRI is studied for selectively pushing these zombie cells to self-destruct. A landmark 2017 study published in the peer-reviewed scientific journal Cell showed that FOXO4-DRI restored physical stamina, renewed coat density (hair regrowth), and improved kidney function in aged mice.

Why researchers reach for FOXO4-DRI

Senolytic research

Studied for selectively triggering the death of senescent cells while leaving healthy cells untouched.

Tissue-ageing models

Restored fitness, fur density and kidney function in naturally aged and accelerated-ageing mice.

Stable D-peptide design

Its retro-inverso structure resists breakdown, giving a longer active window than a normal peptide.

Key features

  • 98%+ purity verified by HPLC
  • D-retro-inverso FOXO4 peptide
  • Lyophilised powder for stability
  • 10 mg research vial
  • Bacteriostatic water included
  • For laboratory research use only

How it works

FOXO4–p53 disruption

In senescent cells, FOXO4 holds p53 in the nucleus to keep the cell alive; FOXO4-DRI competes for that binding.

p53 release

Freed p53 moves to the mitochondria, where it switches on the cell's built-in self-destruct (apoptosis) programme.

Selective targeting

Healthy cells do not rely on this FOXO4–p53 interaction, so they are largely spared.

Research dosage guidelines

Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.

RangeReported doseNote
Reported research range250–500 mcgReference range for laboratory research; no human dosing study has been published.
FrequencyOnce dailyOnce-daily research schedule; no specific time of day has been established.
Typical reconstitution2 mL bacteriostatic waterYields 5 mg/mL.

Tracking this compound? Registered researchers can log active FOXO4-DRI protocols in their private Research Log.

Timing in research protocols

Once daily — no specific time of day has been established.

  • The research schedule uses one administration per day.
  • No human trial has established a preferred clock time or meal relationship.

Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.

Technical specifications

Scientific name
FOXO4 D-retro-inverso peptide (FOXO4-DRI)
Sequence
D-amino-acid retro-inverso FOXO4 (86-131) fused to HIV-TAT cell-penetrating sequence
CAS number
2460055-10-9
Molecular weight
~5358 Da
Purity
98%+ (HPLC)
Form
Lyophilised white powder
Vial size
10 mg
Reconstitution
2 ml bacteriostatic water
Storage (unopened)
-20 degrees C, protected from light
Storage (reconstituted)
2-8 degrees C, use within 30 days

Published research

Peer-reviewed literature on FOXO4-DRI. Links open in a new tab.

Research use notice

FOXO4-DRI is supplied strictly for laboratory research. Published data are preclinical only and no human dosing protocols exist. Not for human or veterinary use, ingestion, or clinical application.

#foxo4-dri#senolytic#senescence#longevity#p53

Cart (0)

Your cart is empty